디지털 바이오 제조 시장은 2024-2031년간 연평균 복합 성장률(CAGR) 13.3%로 성장하여 2031년까지 508억 9,000만 달러에 달할 것으로 예상됩니다.
본 보고서는 광범위한 2차 및 1차 조사, 시장 시나리오에 대한 심층 분석을 통해 주요 산업 촉진요인, 억제요인, 과제 및 기회 분석으로 구성되어 있습니다. 디지털 바이오 제조 시장의 성장은 바이오 의약품에 대한 수요 증가, 주요 기업의 바이오 의약품 공장 역량 강화, 공정 최적화에 대한 수요 증가, 품질 표준 및 규제 준수에 대한 관심 증가, 바이오 의약품의 강력한 R&D 파이프라인, 연속적인 바이오프로세스에 대한 관심 증가가 원동력이 되고 있습니다. 그러나 높은 기술 도입 비용과 복잡한 바이오의약품 개발 및 제조 공정이 이 시장의 성장을 저해하는 요인으로 작용하고 있습니다.
또한, 인더스트리 4.0 기술의 도입, 고급 데이터 분석 도구의 가용성, 바이오프로세스 4.0으로의 전환은 시장 성장의 기회를 창출할 것으로 예상됩니다. 그러나 다운스트림 공정 분석 기술(PAT) 도입의 복잡성과 바이오 의약품 제조에 필요한 집중적인 자본 요구 사항은 디지털 바이오 제조 시장의 주요 과제입니다.
(주 : 주요 5개사의 SWOT 분석을 게재)
Digital Biomanufacturing Market Size, Share, Forecast, & Trends Analysis by Offering (Software [PAT, MES, Digital Twin] Hardware) Functionality (Product Design, Analytics, Automation) Application (MAB, Protein, Vaccine) Bioprocess-Global Forecast to 2031
The digital biomanufacturing market is projected to reach $50.89 billion by 2031, at a CAGR of 13.3% from 2024 to 2031.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the digital biomanufacturing market is driven by growing demand for biologics, capacity expansions of biopharmaceutical plants by key players, increased need for process optimization, increased focus on quality standards & regulatory compliance, strong R&D pipeline for biopharmaceuticals, and rising focus on continuous bioprocessing. However, the high cost of technology deployment and the complex development and manufacturing process of biopharmaceuticals are restraining the growth of this market.
Furthermore, the introduction of industry 4.0 technologies, availability of advanced data analysis tools, and shift towards bioprocessing 4.0 are expected to generate market growth opportunities. However, complexities in process analytical technology (PAT) implementation for downstream processes and intensive capital requirements for biopharmaceutical production are major challenges in the digital biomanufacturing market.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry in the past three to four years. The key players operating in the digital biomanufacturing market are GE Healthcare Technologies Inc. (U.S.), Siemens Xcelerator (Subsidiary of Siemens) (Germany), Cytiva (a subsidiary of Danaher Corporation) (U.S.), ABB Ltd. (Switzerland), Sanofi S.A. (France), Emerson Electric co. (U.S.), Honeywell International Inc. (U.S.), SAP SE (Germany), OVO Biomanufacturing. (U.S.), Schneider Electric SE (France), Dassault Systems (France), Oracle Corporation (U.S.), and 3M (U.S.).
Among all the offerings studied in this report, the software segment is expected to account for the largest share of 74.4% of the digital biomanufacturing market. The rising demand for process optimization coupled with the advantages of software in designing, planning, and manufacturing of drugs or biologics support the large share of this segment.
Among all the functionalities studied in this report, in 2024, the process optimization & analytics segment is expected to account for the largest share of the digital biomanufacturing market. Process optimization and analytics help in improving the manufacturing process by streamlining operating procedures. This involves real-time monitoring and analysis of the activities, which helps the organization in finding bugs in the process or deciding the area of improvement. Moreover, this helps in increasing the efficiency of manufacturing equipment and makes the biomanufacturing process efficient.
Among all the bioprocesses studied in this report, in 2024, the downstream bioprocess segment is expected to account for the largest share of the digital biomanufacturing market. Downstream bioprocesses are considered a complex process in nature that requires continuous monitoring. Digital biomanufacturing software helps in improving and maintaining the workflow of these bioprocesses. This also improves the quality of products. Moreover, the use of predictive technology in the software helps reduce the future complexities associated with downstream bioprocesses, which results in reducing extra costs or future loss. Such factors are driving the growth of the market.
Among all the applications studied in this report, in 2024, the monoclonal antibodies segment is expected to account for the largest share of 48.6% of the digital biomanufacturing market. The availability of funding for monoclonal antibody research and development, approvals for monoclonal antibodies, and increasing production capacity of monoclonal antibody manufacturing plants are contributing to the largest share of the segment.
Among all the end users studied in this report, in 2024, the biopharmaceutical companies segment is expected to account for the largest share of the digital biomanufacturing market. Initiatives focused on improving the adoption of biopharmaceuticals, patent expiration of biologics, and increasing awareness of biopharmaceuticals among physicians are supporting the largest share of the market.
An in-depth analysis of the geographical scenario of the digital biomanufacturing printing market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. Among all the geographies studied in this report, in 2024, North America is expected to account for the largest share of the digital biomanufacturing market. The largest share is attributed to the developed healthcare industry & infrastructure, the presence of major key players, and supportive initiatives focused on improving the adoption of biopharmaceuticals.
Digital Biomanufacturing Market Assessment-by Offering
Digital Biomanufacturing Market Assessment-by Functionality
Note: Other functionalities include Quality management, predictive maintenance, and data storage.
Digital Biomanufacturing Market Assessment-by Bioprocess
Digital Biomanufacturing Market Assessment-by Application
Digital Biomanufacturing Market Assessment-by End User
Digital Biomanufacturing Market Assessment -by Geography
(Note: SWOT analysis of the top 5 companies will be provided.)